首页> 外文期刊>African Journal of Pharmacy and Pharmacology >Ameliorating effect of combination of simvastatin and residronate on glucocorticoid induced osteoporosis model in rats
【24h】

Ameliorating effect of combination of simvastatin and residronate on glucocorticoid induced osteoporosis model in rats

机译:辛伐他汀和雷西膦酸盐联用对糖皮质激素性骨质疏松模型大鼠的改善作用

获取原文
           

摘要

Osteoporosis is one of the major problems facing older people of both sexes. This study was undertaken to investigate the synergistic effects of combination of statins and bisphosphonates in a glucocorticoid-induced osteoporosis (GIO) model. Thirty rats were divided into five groups; control group (I), GIO group (II) (given oral prednisolone, pred 30 mg/kg, per 2 days for 6 weeks), group III (treated by pred + risedronate, risedr 1mg/kg), group IV (treated by pred + simvastatin, sim 10 mg/kg) and group V (treated by pred +sim + risedr). Histological study of the femoral neck bone as well as biochemical assessments of serum alkaline phosphatase (ALP), carboxy-terminal collagen crosslinks (CTX), osteoprotegrin (OPG), leptin, Ca and phosphate were performed. The significant decreases in the trabecular bone thickness, area (p < 0.001), and the significant increase in bone marrow fat cells area (p < 0.001) detected in pred group, were corrected to be nearly similar to control values in groups III, IV and V. Groups that received sim showed better remodeled smoother surfaces bone trabeculae compared with other groups. Combination of sim + risedr shows a significant decrease of bone specific ALP in comparison to pred group (p < 0.05). Also, there was significant decrease of CTX in all treated groups in comparison to pred group (p < 0.05). On other hand, significant improvements of osteoprotegrin levels were noted in all treated groups (p < 0.05), however, there were insignificant changes in leptin levels among groups. In conclusion, addition of statins to bisphosphonate has qualitative rather than quantitative positive effect in experimental osteoporosis which might shorten the duration of therapy and increase efficacy when combined together.
机译:骨质疏松症是男女老年人所面临的主要问题之一。进行这项研究以研究他汀类药物和双膦酸盐类药物在糖皮质激素诱导的骨质疏松症(GIO)模型中的协同作用。 30只大鼠分为5组。对照组(I),GIO组(II)(给予泼尼松龙口服,泼尼松龙30毫克/千克,每2天连续6周),第三组(普瑞德+利塞膦酸盐治疗,瑞塞德1mg / kg),第四组(通过pred +辛伐他汀,sim 10 mg / kg)和V组(pred + sim + risedr治疗)。进行了股骨颈骨的组织学研究以及血清碱性磷酸酶(ALP),羧基端胶原交联键(CTX),骨蛋白原(OPG),瘦素,钙和磷酸盐的生化评估。在pred组中检测到的小梁骨厚度,面积的显着减少(p <0.001)和骨髓脂肪细胞面积的显着增加(p <0.001)被校正为与III,IV组的对照值几乎相似与其他组相比,接受sim的组显示出更好的重塑的平滑表面骨小梁。与pred组相比,sim + risedr的组合显示出骨特异性ALP的显着降低(p <0.05)。此外,与治疗组相比,所有治疗组的CTX均显着降低(p <0.05)。另一方面,在所有治疗组中均观察到了骨蛋白原水平的显着改善(p <0.05),但各组之间的瘦素水平没有显着变化。总之,在双膦酸盐中添加他汀类药物在实验性骨质疏松症中具有定性而非定量的积极作用,这可能会缩短治疗时间并提高疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号